Clinical Trials Logo

Advanced Lung Cancer clinical trials

View clinical trials related to Advanced Lung Cancer.

Filter by:

NCT ID: NCT06326086 Recruiting - Sarcopenia Clinical Trials

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Start date: August 1, 2022
Phase:
Study type: Observational

Lung cancer is a common disease leading to 18 % of cancer deaths worldwide. Despite various improvement in treatment, there still remains low 5-year survival rate of 10-20 % in advanced lung cancer patients. Skeletal muscle mass and physical performance have been shown to effect overall survival and prognosis in lung cancer. This research focuses on effects of different treatment of lung cancer such as chemotherapy, targeted therapy and immunotherapy on skeletal muscle mass and physical performance.

NCT ID: NCT06228209 Recruiting - Clinical trials for Advanced Lung Cancer

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

TIER-PC
Start date: January 26, 2024
Phase: N/A
Study type: Interventional

TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines. In Tier 1, patients who are able to care for themselves and no/mild symptoms receive a community health worker (CHW) trained to elicit illness understanding in a culturally competent way. In Tier 2, for patients with poorer function and mild symptoms, a social worker (SW), trained in serious illness communication, joins the CHW to further elicit patients' goals and prognostic understanding while communicating symptom needs to their primary clinician. In Tier 3, as function decreases and symptoms increase, an advance practice nurse (APN) joins the CHW and SW to manage complex symptoms. Finally, in Tier 4, for those older adults with the poorest function and most complex symptoms, a physician joins the team to ensure that the most complex needs (e.g., end-of-life treatment preferences and multifaceted symptom control) are met. The CHW follows patients longitudinally across all tiers and re-allocates them to the appropriate tier based on their evolving needs.

NCT ID: NCT06183762 Recruiting - Clinical trials for Advanced Lung Cancer

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Start date: January 1, 2020
Phase:
Study type: Observational

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).

NCT ID: NCT06107894 Not yet recruiting - Clinical trials for Advanced Breast Cancer

TIL Therapy for Patients With Advanced Solid Tumors

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This study is a phase I clinical trial to investigate the safety and tolerability of NEOG-100 in patients with advanced breast cancer and lung cancer. NEOG-100, an autologous tumor infiltrating lymphocytes (TILs), is infused intravenously into the patient after non-myeloablative (NMA) lymphodepletion treatment.

NCT ID: NCT06106152 Recruiting - Clinical trials for Advanced Lung Cancer

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Start date: December 5, 2023
Phase: Early Phase 1
Study type: Interventional

This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer

NCT ID: NCT06026111 Recruiting - Clinical trials for Advanced Lung Cancer

Feasibility and Preliminary Efficacy of Exercise During Immunotherapy in Patients With Lung Cancer: The INHALE Trial

INHALE
Start date: December 8, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise intervention is feasible and improves various health outcomes among individuals with advanced lung cancer receiving immunotherapy. The names of the study interventions involved in this study are: - High-intensity interval training (HIIT) (Home-based, virtually supervised, high intensity training in an interval fashion) - Moderate-intensity continuous training (MICT) (Home-based, virtually supervised, moderate intensity in a continuous fashion) - Usual care (UC)

NCT ID: NCT05852002 Completed - Clinical trials for Advanced Lung Cancer

A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer

Start date: April 11, 2023
Phase: N/A
Study type: Interventional

In this research, the patients with advanced lung cancer accompanied by pain and discomfort were treated by injecting freshly manufactured tissue permeable hyaluronan fragment HA35 into the tissue under abdominal adipose.

NCT ID: NCT05815862 Recruiting - Ovarian Cancer Clinical Trials

Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer. Objective response rate (ORR) and progression-free survival (PFS) are the primary endpoints.

NCT ID: NCT05805956 Recruiting - Clinical trials for Advanced Solid Tumor

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Start date: February 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing advanced solid tumors

NCT ID: NCT05664971 Recruiting - Clinical trials for Advanced Lung Cancer

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Start date: February 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with advanced lung cancer